Legend Biotech USA Inc
Industry / private company
Location:
Piscataway, NJ,
United States (USA) (US)
MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT) (2022)
Hillengass J, Cohen AD, Delforge M, Einsele H, Goldschmidt H, Weisel K, Raab MS, et al.
Journal article
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma (2022)
Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, et al.
Journal article
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies (2022)
Cohen AD, Parekh S, Santomasso BD, Gallego Perez-Larraya J, Van De Donk NWCJ, Arnulf B, Mateos MV, et al.
Journal article